09/01/2011 Medical professionals, along with their patients, were notified by the FDA, about an update to the drug label for Reclast (Zoledronic acid). When taking this drug there is a large risk of kidney failure. There have been several cases reported to the FDA about acute renal failure that requires dialysis or fatal outcomes following [...]
Read moreReclast is a zoledronic acid and has been used to treat several ailments for a couple of years but doctors have recently discovered that this once yearly injectable drug has some damaging side effects no one was considering when it first hit the market. Reclast is FDA-approved to treat: Osteoporosis in menopausal women Paget’s disease [...]
Read moreReclast Lawsuit Information Reclast is the brand name for zoledronic acid, a medication that is used to treat pre-osteoporosis conditions in both men and women. Manufactured by Novartis, it was approved by the FDA in June of 2007 for use as a one-time, yearly treatment to be given by injection on an annual basis. More [...]
Read more
Recent Comments